نتائج البحث - "SGLT‐2 inhibitor"

المصدر: Israelsen, S B, Pottegård, A, Sandholdt, H, Madsbad, S, Thomsen, R W & Benfield, T 2021, ' Comparable COVID-19 outcomes with current use of GLP-1 receptor agonists, DPP-4 inhibitors or SGLT-2 inhibitors among patients with diabetes who tested positive for SARS-CoV-2 ', Diabetes, Obesity and Metabolism, vol. 23, no. 6, pp. 1397-1401 . https://doi.org/10.1111/dom.14329Test
Diabetes, Obesity & Metabolism
Diabetes, Obesity and Metabolism

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::95c9668d80fd94d481cc4473761e949eTest
https://pure.au.dk/portal/da/publications/comparable-covid19-outcomes-with-current-use-of-glp1-receptor-agonists-dpp4-inhibitors-or-sglt2-inhibitors-among-patients-with-diabetes-who-tested-positive-for-sarscov2Test(402263cd-ea22-4fd0-afec-5a09c25ed8c5).html

4

Long‐term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52‐week outcomes from the DEPICT ‐1 and ‐2 studies

المؤلفون: Paresh Dandona, Depict Investigators, Depict, Niki Arya, Simon Heller, Paolo Di Bartolo, Lars Hansen, Richard M. Bergenstal, Eiichi Araki, Moshe Phillip, John Xu, Markus F. Scheerer, Nayyar Iqbal, Chantal Mathieu, Marcus Lind, Fredrik Thoren

المصدر: Diabetes, Obesity & Metabolism

مصطلحات موضوعية: Adult, medicine.medical_specialty, Diabetic ketoacidosis, Endocrinology, Diabetes and Metabolism, 030209 endocrinology & metabolism, 030204 cardiovascular system & hematology, Body weight, Placebo, 03 medical and health sciences, chemistry.chemical_compound, dapagliflozin, DEPICT, DKA, insulin adjunct, long‐term data, severe hypoglycaemia, SGLT‐2 inhibitor, T1D, 0302 clinical medicine, Endocrinology, Double-Blind Method, Glucosides, Internal medicine, Internal Medicine, medicine, Humans, Hypoglycemic Agents, In patient, Benzhydryl Compounds, Dapagliflozin, Glycated Hemoglobin, Type 1 diabetes, business.industry, Original Articles, medicine.disease, Diabetes Mellitus, Type 1, Treatment Outcome, Pooled analysis, chemistry, Baseline characteristics, Drug Therapy, Combination, Original Article, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7eeabb346397e1e4e7778837ac220da0Test
https://doi.org/10.1111/dom.14248Test

5

Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis

المؤلفون: Andrei Mircea Catarig, Jack Lawson, Abby Paine, Pierre Johansen, Robert D. Shaw, Matthew Capehorn, Anna Sandberg, Ildiko Lingvay

المصدر: The Journal of Clinical Endocrinology and Metabolism

مصطلحات موضوعية: Male, medicine.medical_specialty, endocrine system diseases, GLP-1 receptor agonist, Endocrinology, Diabetes and Metabolism, Clinical Biochemistry, Glucagon-Like Peptides, Urology, Context (language use), Type 2 diabetes, individual patient data, Biochemistry, Endocrinology, Glucosides, Internal medicine, medicine, Empagliflozin, Humans, Hypoglycemic Agents, Benzhydryl Compounds, Clinical Research Articles, Glucagon-like peptide 1 receptor, Glycated Hemoglobin, Clinical Trials as Topic, business.industry, Semaglutide, Biochemistry (medical), Middle Aged, medicine.disease, Metformin, Confidence interval, Treatment Outcome, indirect comparison, Diabetes Mellitus, Type 2, Meta-analysis, SGLT-2 inhibitor, Drug Therapy, Combination, Female, type 2 diabetes, business, AcademicSubjects/MED00250, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93797ecb6ab061afb7b205a599a86df1Test
https://doi.org/10.1210/clinem/dgaa577Test

6

Eligibility of patients with type 2 diabetes for sodium‐glucose co‐transporter‐2 inhibitor cardiovascular outcomes trials: An assessment using the Diabetes Collaborative Registry

المؤلفون: Eric Wittbrodt, Suzanne V. Arnold, Fengming Tang, David Chamberlain, Mikhail Kosiborod

المصدر: Diabetes, Obesity & Metabolism

مصطلحات موضوعية: Male, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, Eligibility Determination, 030209 endocrinology & metabolism, Type 2 diabetes, 030204 cardiovascular system & hematology, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, cardiovascular disease, Internal medicine, Diabetes mellitus, Prevalence, Internal Medicine, Humans, Hypoglycemic Agents, Medicine, Generalizability theory, In patient, Registries, Sodium-Glucose Transporter 2 Inhibitors, Aged, business.industry, Atherosclerotic cardiovascular disease, Brief Report, Patient Selection, Middle Aged, Atherosclerosis, medicine.disease, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Brief Reports, observational study, Female, Observational study, type 2 diabetes, Trial Eligibility Criteria, business, Cardiovascular outcomes, SGLT‐2 inhibitor, Diabetic Angiopathies

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84b6d2e74ecc41dce2827e62b8029f5dTest
https://doi.org/10.1111/dom.13738Test

7

SGLT-2 inhibitors for treatment of heart failure in patients with and without type 2 diabetes: A practical approach for routine clinical practice

المؤلفون: Giaccari, Andrea, Pontremoli, R., Perrone Filardi, P.

المساهمون: Giaccari, A., Pontremoli, R., Perrone Filardi, P.

المصدر: International journal of cardiology. 351

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8caea76f35b7f9cf39dd34c3875115a4Test
https://pubmed.ncbi.nlm.nih.gov/35134445Test

8

The nephrological perspective on SGLT-2 inhibitors in type 1 diabetes

المؤلفون: Oliver Schnell, Pieter Gillard, Per-Henrik Groop

المساهمون: Pathology/molecular and cellular medicine, Diabetes Pathology & Therapy, Diabetes Clinic, HUS Abdominal Center, Research Programs Unit, Department of Medicine, Per Henrik Groop / Principal Investigator, Clinicum, Nefrologian yksikkö, University of Helsinki, Helsinki University Hospital Area, CAMM - Research Program for Clinical and Molecular Metabolism

مصطلحات موضوعية: CHRONIC KIDNEY-DISEASE, Male, Diabetes Mellitus, Type 2/drug therapy, endocrine system diseases, medicine.medical_treatment, Endocrinology, Diabetes and Metabolism, DOUBLE-BLIND, 0302 clinical medicine, Endocrinology, Insulin, SGLT inhibition, Diabetic Nephropathies, 030212 general & internal medicine, Body mass index, METABOLIC SYNDROME, RISK, COMPLICATIONS, Diabetes, STAGE RENAL-DISEASE, GLOMERULAR HYPERFILTRATION, General Medicine, Kidney disease, Nephrology, Insulin/therapeutic use, Female, medicine.medical_specialty, Renal effects, Diabetes Mellitus, Type 1/drug therapy, Type 1 diabetes mellitus, Renal function, 030209 endocrinology & metabolism, Hypoglycemic Agents/therapeutic use, URIC-ACID, 03 medical and health sciences, Diabetes mellitus, Internal medicine, BASE-LINE CHARACTERISTICS, Internal Medicine, medicine, Hypoglycemic Agents, Humans, COTRANSPORTER 2 INHIBITORS, Diabetic kidney disease, Renal Insufficiency, Chronic, Sodium-Glucose Transporter 2 Inhibitors, Type 1 diabetes, Renal Insufficiency, Chronic/drug therapy, business.industry, Sodium-Glucose Transporter 2 Inhibitors/therapeutic use, Type 2 Diabetes Mellitus, nutritional and metabolic diseases, medicine.disease, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, 3121 General medicine, internal medicine and other clinical medicine, SGLT-2 inhibitor, Adjunctive treatment, Diabetic Nephropathies/drug therapy, Metabolic syndrome, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03aec7f8c17f21dae029eac6142bfa4cTest
https://biblio.vub.ac.be/vubir/the-nephrological-perspective-on-sglt2-inhibitors-in-type-1-diabetesTest(a44fea01-9080-41df-b6e2-d8cafdc8e82c).html

9

Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post-hoc analysis of concomitant add-on versus sequential add-on to metformin and of triple versus dual therapy with metformin

المؤلفون: Julio Rosenstock, Eva Johnsson, Nayyar Iqbal, Lars Hansen, Hungta Chen, Stefano Del Prato, Chantal Mathieu, Ricardo Garcia-Sanchez

المصدر: Diabetes, Obesity & Metabolism

مصطلحات موضوعية: Male, endocrine system diseases, Endocrinology, Diabetes and Metabolism, Adamantane, Type 2 diabetes, Saxagliptin, law.invention, chemistry.chemical_compound, 0302 clinical medicine, Endocrinology, Randomized controlled trial, Glucosides, law, 030212 general & internal medicine, Dapagliflozin, Brief Report, DPP‐4 inhibitor, Dipeptides, Middle Aged, DOUBLE-BLIND TRIAL, Metformin, Treatment Outcome, Tolerability, Drug Therapy, Combination, Female, type 2 diabetes, Life Sciences & Biomedicine, SGLT‐2 inhibitor, medicine.drug, medicine.medical_specialty, Urology, TYPE-2 DIABETES-MELLITUS, 030209 endocrinology & metabolism, EVENTS, 03 medical and health sciences, Endocrinology & Metabolism, Double-Blind Method, DPP-4 inhibitor, SGLT-2 inhibitor, dapagliflozin, metformin, Internal Medicine, medicine, Humans, Hypoglycemic Agents, Benzhydryl Compounds, Adverse effect, Sodium-Glucose Transporter 2 Inhibitors, Glycated Hemoglobin, Dipeptidyl-Peptidase IV Inhibitors, Science & Technology, business.industry, nutritional and metabolic diseases, medicine.disease, EFFICACY, Hypoglycemia, chemistry, Diabetes Mellitus, Type 2, PLUS METFORMIN, Concomitant, Brief Reports, business

وصف الملف: Print-Electronic

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1088146dd05115bef5b32a1a3362bb43Test
https://lirias.kuleuven.be/handle/123456789/634001Test

10

SGLT-2 Inhibitors: Are They a Promising Treatment Option in T2DM Patients with NAFLD?

المؤلفون: Dimitrios Patoulias

المصدر: Acta Medica, Vol 60, Iss 4, Pp 167-170 (2018)

مصطلحات موضوعية: 0301 basic medicine, T2DM, lcsh:Medicine, 030209 endocrinology & metabolism, Disease, Bioinformatics, 03 medical and health sciences, 0302 clinical medicine, Liver Function Tests, Sodium-Glucose Transporter 2, Non-alcoholic Fatty Liver Disease, NAFLD, medicine, Animals, Humans, Hypoglycemic Agents, In patient, Sodium-Glucose Transporter 2 Inhibitors, Beneficial effects, Glycemic, medicine.diagnostic_test, business.industry, lcsh:R, Fatty liver, nutritional and metabolic diseases, Treatment options, General Medicine, medicine.disease, digestive system diseases, Clinical Practice, Glucose, Treatment Outcome, 030104 developmental biology, Diabetes Mellitus, Type 2, SGLT-2 inhibitor, Liver function tests, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4efc34fb5d491387ec8c20cd5b2821d7Test
https://doi.org/10.14712/18059694.2018.15Test

تنقيح النتائج